# Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial

Study · id `cardio:ct-nct01196819` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01196819](<https://clinicaltrials.gov/study/NCT01196819>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01196819

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

## Technical summary

Registry record NCT01196819. Randomized; double masking; primary purpose treatment. Start 2010-09 (actual); primary completion 2012-05 (actual). Results posted on 2018-02-22.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 458 participants (enrolled count; ClinicalTrials.gov record NCT01196819, source copy `cardio:ctgov-nct01196819-2019-07-30`, retrieved 2026-10-26)
- Started: 2010-09 (actual) (ClinicalTrials.gov record NCT01196819, source copy `cardio:ctgov-nct01196819-2019-07-30`, retrieved 2026-10-26)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01196819, source copy `cardio:ctgov-nct01196819-2019-07-30`, retrieved 2026-10-26)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT01196819, source copy `cardio:ctgov-nct01196819-2019-07-30`, retrieved 2026-10-26)
- Results first posted: 2018-02-22 (ClinicalTrials.gov record NCT01196819, source copy `cardio:ctgov-nct01196819-2019-07-30`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01196819, source copy `cardio:ctgov-nct01196819-2019-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01196819-2019-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
- Condition: Coronary Artery Disease
- Intervention (Device): Firehawk
- Intervention (Device): Xience V
- Lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd. (`cardio:org-shanghai-microport-medical-group-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial (`cardio:pubmed-23685298`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: \[Long term safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of coronary de novo lesions\] (`cardio:pubmed-29166720`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 491df589ccdd5353e46e6ba7a81b9d1c83bd9075174dbe6e51ab0636a38562a5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
